两种方法治疗新生血管性青光眼的临床观察

Clinical observation of two methods in treatment of neovascular glaucoma

摘要:

目的：观察玻璃体腔内注射康柏西普联合小梁切除术或联合Ahmed青光眼引流阀植入术治疗新生血管性青光眼(NVG)的临床疗效。

方法：回顾分析2016-02/2017-06我院收治的NVG患者40例40眼，根据治疗方法分为A组(康柏西普联合小梁切除术+全视网膜光凝)和B组(康柏西普联合Ahmed青光眼引流阀植入术+全视网膜光凝)，每组20例20眼。治疗后随访6mo，观察患者视力、眼压、眼压控制率和新生血管消退情况等。

结果：治疗前，两组患者眼压比较无差异(P>0.05)。治疗后6mo，B组眼压低于A组(P<0.05)，但两组视力、眼压控制率、新生血管消退情况无差异(均P>0.05)。

结论：玻璃体腔注射康柏西普联合Ahmed青光眼引流阀植入和康柏西普联合小梁切除术治疗NVG安全有效，前者术式降眼压幅度更大。

Abstract:

AIM: To observe the clinical efficacy of intravitreal injection of conbercept combined with trabeculectomy and conbercept combined with Ahmed glaucoma valve implantation in treatment of neovascular glaucoma(NVG).

METHODS: Totally 40 cases(40 eyes)of NVG patients selected from our hospital from February 2016 to June 2017 were retrospectively analyzed. According to the treatment methods, they were divided into group A(conbercept with trabeculectomy+ panretinal photocoagulation)and group B(conbercept combined with Ahmed glaucoma valve implantation+ panretinal photocoagulation), 20 cases(20 eyes)in each group. The visual acuity, intraocular pressure, intraocular pressure control rate, neovascularization were observed after 6mo follow-up.

RESULTS: Before treatment, there was no significant difference in intraocular pressure between the two groups(P>0.05). The intraocular pressure in group B was lower than that in group A(P<0.05)at 6mo after treatment, but there was no significant difference in visual acuity, intraocular pressure control rate and the regression of neovascularization between the two groups(All P>0.05).

CONCLUSION: Intravitreal injection of conbercept combined with Ahmed glaucoma valve implantation and conbercept combined with trabeculectomy for NVG are safe and effective, but the former is more effective in reducing intraocular pressure.